SHENZHEN, China, March 1 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) and its China based subsidiary Mellow Hope announce that the company held Final Evaluation Meeting for Registration Approval of Cerebroprotein Hydrolysate for Injection medicine (Brand Name: Nutriprotein) in Mumbai, India.
HTDS held a successful Final Evaluation Meeting with the Indian DCGI (Drug Controller General of India) on its Cerebroprotein Hydrolysate for Injection. Mellow Hope has been conducting the clinical trials for the Indian market approval since April 2009. The company enters final stage of product quality testing, and will send new batch sample to the DCGI for quality reconfirmation by the end of March and, subsequently, DCGI will issue Registration Certificate for this medicine.
The company believes that, once approved, HTDS will be the only supplier of this product to India, and estimates Nutriprotein market size to 2 to 3 million doses annually.
Nutriprotein medicine is a unique brain nutrient that helps the Central Nervous System in regulating and improving nerve cell metabolism, promoting synapse generation, inducing nerve cell differentiation and protecting nerve cells against damages by ischemia, neurotoxins, etc.
The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/ should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support site to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
